Future larger registry-based/multi-center studies should be undertaken to further our understanding of the role for GLP-1-based anti-diabetic therapy in the increased Sdc-1 expression in the adventitia of T2D patients and its potential relevance for the reduced prevalence of ascending AAs in T2D. This evidence concerns the gene SDC1 and type 2 diabetes mellitus.